Conduit Total Assets from 2010 to 2024

CDT Stock

0.09 0 4.47%

Conduit Pharmaceuticals Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2010-12-31

Previous Quarter

7.2 M

Current Value

7.6 M

Quarterly Volatility

2.5 M

Credit Downgrade

Yuan Drop

Covid

Check Conduit Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Conduit Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 159.5 K, Selling General Administrative of 4.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Conduit financial statements analysis is a perfect complement when working with Conduit Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Conduit Pharmaceuticals Correlation against competitors.

For more information on how to buy Conduit Stock please use our How to Invest in Conduit Pharmaceuticals guide.

Latest Conduit Pharmaceuticals' Total Assets Growth Pattern

Below is the plot of the Total Assets of Conduit Pharmaceuticals over the last few years. Total assets refers to the total amount of Conduit Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Conduit Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Conduit Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Conduit Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 7.22 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Conduit Total Assets Regression Statistics

	Arithmetic Mean	1,158,113
	Geometric Mean	266,331
	Coefficient Of Variation	219.11
	Mean Deviation	1,665,730
	Median	213,125
	Standard Deviation	2,537,548
	Sample Variance	6.4T
	Range	7.6M
	R-Value	0.58
	Mean Square Error	4.6T
	R-Squared	0.34
	Significance	0.02
	Slope	330,818
	Total Sum of Squares	90.1T

Conduit Total Assets History

	2024	7.6 M
	2023	7.2 M
	2022	5000.0

Other Fundumenentals of Conduit Pharmaceuticals

Intangibles To Total Assets

Conduit Pharmaceuticals Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Long Term Debt	Total Liab	Net Invested Capital	Total Current Assets	Short Term Debt	Common Stock	Deferred Long Term Liab	Short Long Term Debt	Net Working Capital	Intangible Assets
Total Assets		0.9	-0.69	-0.99	-0.82	0.7	0.52	0.95	1.0	1.0	-0.13	-0.95	0.95	1.0	-0.95
Total Stockholder Equity	0.9		-0.3	-0.95	-0.48	0.36	0.09	0.99	0.85	0.89	-0.55	-0.83	0.85	0.89	-0.83
Net Tangible Assets	-0.69	-0.3		0.57	0.98	-0.94	-0.97	-0.43	-0.76	-0.71	-0.63	0.69	-0.66	-0.71	0.69
Net Debt	-0.99	-0.95	0.57		0.72	-0.61	-0.37	-0.99	-0.97	-0.98	0.28	0.92	-0.95	-0.98	0.92
Retained Earnings	-0.82	-0.48	0.98	0.72		-0.94	-0.91	-0.6	-0.87	-0.83	-0.47	0.8	-0.78	-0.83	0.8
Long Term Debt	0.7	0.36	-0.94	-0.61	-0.94		0.86	0.48	0.76	0.71	0.55	-0.59	0.78	0.72	-0.59
Total Liab	0.52	0.09	-0.97	-0.37	-0.91	0.86		0.22	0.59	0.53	0.77	-0.55	0.47	0.53	-0.55
Net Invested Capital	0.95	0.99	-0.43	-0.99	-0.6	0.48	0.22		0.92	0.94	-0.43	-0.89	0.9	0.94	-0.89
Total Current Assets	1.0	0.85	-0.76	-0.97	-0.87	0.76	0.59	0.92		1.0	-0.04	-0.95	0.95	1.0	-0.95
Short Term Debt	1.0	0.89	-0.71	-0.98	-0.83	0.71	0.53	0.94	1.0		-0.11	-0.95	0.95	1.0	-0.95
Common Stock	-0.13	-0.55	-0.63	0.28	-0.47	0.55	0.77	-0.43	-0.04	-0.11		0.1	-0.1	-0.1	0.1
Deferred Long Term Liab	-0.95	-0.83	0.69	0.92	0.8	-0.59	-0.55	-0.89	-0.95	-0.95	0.1		-0.81	-0.95	1.0
Short Long Term Debt	0.95	0.85	-0.66	-0.95	-0.78	0.78	0.47	0.9	0.95	0.95	-0.1	-0.81		0.96	-0.81
Net Working Capital	1.0	0.89	-0.71	-0.98	-0.83	0.72	0.53	0.94	1.0	1.0	-0.1	-0.95	0.96		-0.95
Intangible Assets	-0.95	-0.83	0.69	0.92	0.8	-0.59	-0.55	-0.89	-0.95	-0.95	0.1	1.0	-0.81	-0.95

Click cells to compare fundamentals

About Conduit Pharmaceuticals Financial Statements

Conduit Pharmaceuticals shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Conduit Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Conduit Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Conduit Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	7.2 M	7.6 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Conduit Stock Analysis

When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC